Massachusetts General Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Acta Cytol. 2022;66(1):1-13. doi: 10.1159/000518579. Epub 2021 Sep 27.
Fine-needle aspiration (FNA) is a well-established method for sampling breast lesions with high accuracy and positive predictive value. Despite its decline in recent years relative to the use of core needle biopsies, there are several advantages to FNA which include cost-effectiveness, low complication rate, and the ability to perform rapid on-site evaluation (ROSE). The aim of this study was to evaluate breast FNAs with ROSE to identify diagnostic challenges during ROSE.
We identified all breast FNAs with ROSE performed at Massachusetts General Hospital from January 2014 to December 2019. From the electronic medical record, clinical, radiological, and follow-up pathology results were recorded. Comparison between the rapid and final cytological diagnosis was made. All discrepancies were documented with major discrepancy defined as a malignant rapid interpretation not confirmed on final diagnosis or a negative rapid interpretation upgraded to suspicious or positive on final diagnosis.
The study cohort consisted of 483 breast FNAs with ROSE. The rapid and final cytological interpretations showed good correlation, with only 6 (1.2%) major discrepancies. Problematic areas included low-grade, lobular, and fibroepithelial lesions with low cellularity being a contributory factor to misclassification.
FNA remains a highly accurate method for the evaluation of breast lesions with ROSE.
细针穿刺(FNA)是一种准确性和阳性预测值都很高的乳腺病变取样方法。尽管近年来相对于使用核心针活检,FNA 的使用有所下降,但 FNA 仍有几个优势,包括成本效益高、并发症发生率低,以及能够进行快速现场评估(ROSE)。本研究的目的是评估有 ROSE 的乳腺 FNA,以确定 ROSE 期间的诊断挑战。
我们从 2014 年 1 月至 2019 年 12 月,在马萨诸塞州综合医院确定了所有有 ROSE 的乳腺 FNA。从电子病历中记录了临床、影像学和随访的病理结果。对 ROSE 的快速和最终细胞学诊断进行了比较。记录了所有的差异,主要差异定义为快速恶性解读未在最终诊断中得到证实,或快速阴性解读在最终诊断中升级为可疑或阳性。
本研究队列包括 483 例有 ROSE 的乳腺 FNA。快速和最终细胞学解读显示出良好的相关性,只有 6 例(1.2%)主要差异。有问题的领域包括低级别、小叶性和纤维上皮性病变,细胞数量低是导致分类错误的一个因素。
FNA 仍然是一种高度准确的评估乳腺病变的方法,有 ROSE。